Colon cancer and gene alterations: Their immunological implications and suggestions for prognostic indices and improvements in biotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 5, 2006, Pages 488-505

  Contasta, Ida ^a   Pellegrini, Patrizia ^a   Berghella, Anna Maria ^a   Del Beato, Tiziana ^a   Adorno, Domenico ^a  

^a CNR   (Italy)

Author keywords

Bcl 2; c Ki ras; Cancer biotherapy; Colon cancer; Gene alterations; Immunological parameters; p53

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7; INTERLEUKIN 8; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RAS PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER PREVENTION; CELL DIVISION; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; COLON CARCINOMA; CYTOKINE RELEASE; FEMALE; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR SUPPRESSOR GENE;

COLONIC NEOPLASMS; GENES, BCL-2; GENES, P53; GENES, RAS; HUMANS; INTERLEUKIN-4; PROGNOSIS; TH1 CELLS; TH2 CELLS;

EID: 33751037845     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.488     Document Type: Article

References (106)

1. Perucho M, Forrester K, Almoguera C, et al. Expression and mutational activation of the c-Ki-ras gene in human carcinomas. Cancer Cells 1989;7:137.
2. Bishop JM. The molecular genetics of cancer. Science 1987;235:305.
3. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell 1991;64:281.
4. Bos JL. ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682.
5. Sluyser M. (Ed). In: The Molecular Biology of Cancer Genes. Chichester: Horwood E, 1990;82.
6. Lemoine NR. In: Carney D, Sikora K., eds. Genes and Cancer. Chichester, UK: John Wiley & Sons, 1990.
7. Hall A. The cellular functions of small GTP-binding proteins. Science 1990;249:635.
8. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: A conserved switch for diverse cell functions. Nature 1990;348:125.
9. Mitsudomi T, Steinberg SM, Oie HK, et al. ras gene mutations in non-small-cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999.
10. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561.
11. Cappella G, Cronauer-Mitra S, Peinado MA, et al. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Env Health Persp 1991;93:125.
12. Isobe M, Emanuel BS, Givol D, et al. Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986;320:84.
13. Wilson RH, Whiteside MCR, Russell SEH. Molecular genetics of colorectal cancer (part 1). Clin Oncol 1997;9:14.
14. Bischoff JR, Friedman PN, Marshak DR, et al. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 1990;87:4766.
15. Diller L, Kassel J, Nelson CE, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772.
16. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352: 7345.
17. Kern SE, Kinzles K, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708.
18. Kern SE, Kinzles K, Baker SJ, et al. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 1991;6:131.
19. O'Rourke RW, Miller CW, Kato GJ, et al. A potential transcriptional activation element in the p53 protein. Oncogene 1990;5:1829.
20. Friedman P, Kern S, Vogelstein B, et al. Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc Natl Acad Sci USA 1990;87:9275.
21. Campo E, de la Calle-Martin O, Miquel R, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. PalaCancer Res 1991;51:4436.
22. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705.
23. Baker SJ, Fearon ER, Nigro JM. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244(4901):217.
24. Elihayu D, Goldfinger N, Pinhasi-Kimhi O, et al. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 1988;3:313.
25. Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531.
26. Berghella AM, Pellegrini P, Piancatelli D, et al. Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, 1L-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother 1994;38:160.
27. Pellegrini P, Berghella AM, Del Beato T, et al. Immunological directives for biotherapy improvement in the treatment of colorectal cancer. Cancer Biother Radiopharm 1996;11(2):113.
28. + T-cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996;42:1.
29. Cher DJ, Mosmann TR. Two types of murine helper T-cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987;138:3688.
30. Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T-cells. Nature 1988;334:255.
31. Chatelain R, Varkila K, Coffman LR. IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol 1992;148:1182.
32. Kopf M, Le Gros G, Bachman M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245.
33. + T-cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589.
34. Schwarz EM, Salgame P, Bloom BR. Molecular regulation of human interleukin-2 and T-cell function by interleukin-4. Proc Natl Acad Sci USA 1993;90: 7734.
35. Smith C, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;248:1019.
36. Namen AE, Schmierer AE, March CJ, et al. B-cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988;167:988.
37. Namen AE, Lupton S, Hjerrild J, et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1998;333:571.
38. Morrissey PJ, Goodwill RG, Nordan RP, et al. Recombinant interleukin-7, pre-B-cell growth factor, has costimulatory activity on purified mature T-cells. J Exp Med 1989;169:707.
39. Grabstein KH, Namen AE, Shanerbeck K, et al. Regulation of T-cell proliferation by IL-7. J Immunol 1990;144:3015.
40. Lynch DH, Miller RE. Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol 1990;145:1983.
41. Hickman CJ, Crim IA, Mostowski HS, et al. Regulation of human cytotoxic T-lymphocyte development by IL-7. J Immunol 1990;145:2415.
42. Alderson MR, Tough TW, Ziegler SF, et al. Interleukin-7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991;173:923.
43. Leonard EJ, Skeel A, Yoshimura T, et al. Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. J Immunol 1990;144:1323.
44. Larsen CG, Anderson AO, Appella E, et al. The neutrophil-activating protein (NAP-1) is also chemotactic for T-lymphocytes. Science 1989;243:1464.
45. Solomkin JS, Bass RC, Bjomson HS, et al. Alterations of neutrophil responses to tumor necrosis factor alpha and interleukin-8 following human endotoxemia. Infect Immun 1994;62:943.
46. Webb DSA, Mostowski HS, Gerrard TL. Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol 1991;146:3682.
47. Springer TA. Adhesion receptors of the immune system. Nature 1990;346;425.
48. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989;34:619.
49. Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol 1991;147:3788.
50. Kitagawa K, Matsumoto M, Sasaki T, et al. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis 2002; 160(2):305.
51. Contasta I, Pellegrini P, Berghella AM, et al. Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm 1996;11:373.
52. Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol 1991;147:3788.
53. Albert-Wolf M, Meuer SC, Wallich R. Dual function of recombinant human CD58: Inhibition of T-cell adhesion and activation via the CD2 pathway. Int Immunol 1991;3:1335.
54. + phenotype. Int Arch Aller Immunol 1993;100:201.
55. + T-cell subsets in vivo. Immunol Rev 1991;123:189.
56. Gregely M, Benczur A, Erdei A. In: Progress in Immunology VIII. Budapest, Hungary: Springer Hungarica, 347.
57. + T helper cell subsets. Curr Opin Immunol 1993;5:391.
58. Swain SL, Bradley LM, Croft M, et al. Helper T-cell subsets: Phenotype, function, and the role of lymphokines in regulating their development. Immunol Rev 1991;123:115.
59. + T-cells from T-cell receptor transgenic mice. J Exp Med 1992;176: 1091.
60. Tanaka T, Hu-Li J, Seder RA, et al. Interleukin-4 suppresses interleukin-2 and interferon gamma production by naïve T-cells stimulated by accessory cell-dependent receptor engagement. Proc Natl Acad Sci USA 1993;90:5914.
61. Pfeifer J, McKenzie D, Swain S, et al. B-cell stimulatory factor-1 (interleukin-4) is sufficient for the proliferation and differentiation of lectin-stimulated cytolytic T-lymphocyte precursors. J Exp Med 1987; 166:1464.
62. - cells that make TH2 cytokines and help B-cells. Science 1993;260:1802.
63. Mulé JJ, Custer MC, Travis WD, et al. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992;148:2622.
64. Takai Y, Waong GG, Clark SC, et al. B-cell stimulatory factor-2 is involved in the differentiation of cytotoxic T-lymphocytes. J Immunol 1988;140:508.
65. Gajewski TF, Pinnas M, Wong T, et al. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol 1991;146:1750.
66. + human T-lymphocyte subsets. Eur J Immunol 1993;23:61.
67. Welge T, Wolf M, Jaggle C, et al. Human naïve T-cells are preferentially stimulated by crosslinking of CD3 and CD45RA with monoclonal antibodies. Cell Immunol 1993;148:218.
68. Williams ME, Lichtman AH, Abbas KA. Anti-CD3 antibody induces unresponsiveness to IL-2 in Th1 clones but not in Th2 clones. J Immunol 1990; 144:1208.
69. Downward J, Graves JD, Warne PH, et al. Stimulation of p21ras upon T-cell activation. Nature (London) 1990;346:719.
70. Burmer GC, Loeb LA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci USA 1989;86:2403.
71. Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T-cells and NK-cells in colorectal tumor-infiltrating, gut mucosal, and peripheral lymphocytes: Correlation with the stage of the disease. Int J Cancer 1995;61:765.
72. Waterfield MD, Scrace GT, Whittle N, et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983;304:35.
73. Rooney JW, Hodge MR, McCaffrey PG, et al. A common factor regulates both Th1- and Th2-specific cytokine gene expression. EMBO J 1994;13(3):625.
74. Chensue SW, Ruth JH, Warmington K, et al. In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine-mediated granuloma formation. J Immunol 1995;155(7):3546.
75. Wynn TA, Cheever AW, Jankovic D, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995; 376:594.
76. Contasta I, Pellegrini P, Berghella AM, et al. Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: Indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding. Cancer Biother Radiopharm 1997;12(6): 385.
77. Thomson A. (Ed.). In: The cytokine handbook. San Diego, CA: Academic Press, 1994.
78. Berghella AM, Pellegrini P, Del Beato T, et al. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 1998;45:241.
79. Zampetti GP, Olson D, Labow M, et al. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc Natl Acad Sci USA 1992;89:3952.
80. Contasta I, Pellegrini P, Berghella AM, et al. Cell cycle control in cellular homeostasis during the immune response: Interactions between TH1, TH2 cytokines, and Bcl-2 and p53 molecules. Cancer Biother Radiopharm 2001;16(1):63.
81. Chao DT, Korsmeyer SJ. Bcl-2 family: Regulators of cell death. Ann Rev Immunol 1998;6:395.
82. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Ann Rev Immunol 1995;13:513.
83. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335(6189): 440.
84. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1988;281(5381):1322.
85. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996;15(24):6979.
86. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996;13(7):1511.
87. Linette GP, Li Y, Roth K, et al. Cross talk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA 1996;93(18):9545.
88. Shibasaki F, Kondo E, Akagi T, et al. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997;386(6626):728.
89. +)- activated cell death in mammalian cells. J Cell Biol 1995;131(3):735.
90. Rothenberg EV. The development of functionally responsive T-cells. Adv Immunol 1992;51:85.
91. Gratiot-Deans J, Ding L, Turka LA, et al. Bcl-2 proto-oncogene expression during human T-cell development. Evidence for biphasic regulation. J Immunol 1993;151(1):83.
92. Veis DJ, Sentman CL, Bach EA, et al. Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T-lymphocytes. J Immunol 1993; 151(5):2546.
93. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74(4):597.
94. Kirchgessner CU, Patil CK, Evans JW, et al. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995;267(5201):1178.
95. Symonds H, Krall L, Remington L, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78(4):703.
96. Bloom BR, Salgame P, Diamond B. Revisiting and revising suppressor T-cells. Immunol Today 1992;4:131.
97. Cerezo A, Martinez-A C, Gonzalez A. IL-2 deprivation triggers apoptosis which is mediated by c-Jun N-terminal kinase 1 activation and prevented by Bcl-2. Cell Death Diff 1999;6(1):87.
98. Cohen SB, Crawley JB, Kahan MC, et al. Interleukin-10 rescues T-cells from apoptotic cell death: Association with an upregulation of Bcl-2. Immunology 1997;92(1):1.
99. Noble KE, Wickremasinghe RG, DeCornet C, et al. Monocytes stimulate expression of the Bcl-2 family member, A1, in endothelial cells and confer protection against apoptosis. J Immunol 1999;162(3):1376.
100. Akbar AN, Borthwick NJ, Wickremasinghe RG, et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T-cell apoptosis in response to growth factor withdrawal: Selective induction of anti-apoptotic (Bcl-2, Bcl-xL) but not proapoptotic (Bax, Bcl-xS) gene expression. Eur J Immunol 1996;26(2):294.
101. Li L, Krajewski S, Reed JC, et al. The apoptosis and proliferation of SAC-activated B-cells by IL-10 are associated with changes in Bcl-2, Bcl-xL, and Mcl-1 expression. Cell Immunol 1997;178(1):33.
102. Huang HM, Li JC, Hsieh YC, et al. Optimal proliferation of a hematopoietic progenitor cell line requires either costimulation with stem cell factor or increase of receptor expression that can be replaced by overexpression of Bcl-2. Blood 1999;93(8):2569.
103. Klefstrom J, Arighi E, Littlewood T, et al. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappa-β activation. EMBO J 1997;16(24):7382.
104. Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa-β activation. Mol Cell Biol 1995;15(5):2809.
105. McKinsey TA, Brockman JA, Scherer DC, et al. Inactivation of IkappaBbeta by the tax protein of human T-cell leukemia virus type I: A potential mechanism for constitutive induction of NF-kappaB. Mol Cell Biol 1999;16(5):2083.
106. de Moissac D, Mustapha S, Greenberg AH, et al. Bcl-2 activates the transcription factor NF-kappa-B through the degradation of the cytoplasmic inhibitor Ikappa-B-alpha. J Biol Chem 1998;273(37):23946.